AIDS News and Research

RSS

Raltegravir could be valid target against all Herpesviridae

Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Merck under the name Isentress, cancels the function of an essential protein for the replication of one kind of herpes virus.

23 Sep 2010

St. Jude Medical to highlight OCT product platform at TCT meeting

St. Jude Medical, Inc., a global medical device company, will highlight recently launched technology, including its new Optical Coherence Tomography (OCT) product platform, at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.

23 Sep 2010

LSUHSC hosts international scientific conference on drug abuse research and politics

Topics ranging from the future of addiction research and treatment to the binational implications of Mexico's decriminalization of drugs will be presented at the 10th Annual International Conference of the National Hispanic Science Network (NHSN) on Drug Abuse September 30 - October 2, 2010 at The Westin New Orleans Canal Place.

23 Sep 2010

World leaders address country ownership, accountability, women at MDG summit

At the U.N. Summit on the Millennium Development Goals (MDGs) on Tuesday African leaders said "they could do more to meet U.N. goals to slash extreme poverty and urged stronger leadership among developing countries to tackle hunger and disease and attract investment," Reuters reports in an article that examines the leaders' call for African nations to take greater ownership over their development.

23 Sep 2010

Merck expands patient assistance programs to provide medicines to needy people

Today, Merck announced that it has significantly expanded the number of Merck medicines available through its Merck Helps patient assistance programs, which include the Merck Patient Assistance Program, the Merck Vaccine Patient Assistance Program, the ACT Program for Oncology and Hepatitis C medicines, and the SUPPORT Program for HIV/AIDS medicines.

23 Sep 2010

Opinions: Genetically-modified crops can improve vaccines; MDG focus on women and girls; U.S. leadership for MDGs; Boosting access to drugs; Merits of bilateral development assistance

"The U.N. estimates that diarrheal diseases kill 1.8 million people every year. … So you might take it as good news that American company Ventria Bioscience says it has hit on an improvement to existing rehydration therapies, which could mean another tool in the fight against diarrhea," according to a Wall Street Journal editorial examining the delays the company has experienced since it first sought to have its product approved by the FDA back in 2004, even "[a]fter a panel of food, medicine, immunology, child nutrition and health experts had declared its product safe."

23 Sep 2010

N.J. Democrats fail to restore funds to family-planning centers; Penn. reports record number eligible for Medicaid; N.Y. report suggests overhauling Medicaid system

Philadelphia Inquirer: Efforts by N.J. Senate Democrats to restore $7.5 million to state family planning health centers ended Monday without any Republican support. In a 23-17 party line vote the Senate failed veto the governor's veto of center funding. Gov. "Christie's budget eliminated state funding to 58 family-planning health centers across the state, which last year provided services to more than 130,000 men and women, most of whom were underinsured.

22 Sep 2010

UC researcher receives NIDA’s Avant-Garde Award for cocaine addiction research

A University of Cincinnati (UC) researcher will receive $2.5 million over five years from the National Institute on Drug Abuse (NIDA) to support his work on a potential immunotherapy for cocaine addiction.

22 Sep 2010

NIDA's Avant-Garde Awards support novel approaches for treating tobacco and cocaine addiction

A potential immunotherapy, a new gene therapy, an enzyme inhibitor, and a compound originally isolated from a Chinese herb are among the latest approaches scientists are proposing to treat addiction.

22 Sep 2010

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Dutch biopharmaceutical company Crucell N.V. and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35.

22 Sep 2010

Specific orofacial characteristics can lead to accurate diagnosis of fetal alcohol spectrum disorders

Fetal alcohol spectrum disorders (FASD) is an umbrella term that describes the range of effects that can occur in a person whose mother drank alcohol while pregnant. Each year, FASD affect an estimated 40,000 infants in the United States—more than spina bifida, Down syndrome, and muscular dystrophy combined.

22 Sep 2010

Secretary-General opens U.N. summit on MDGS with appeal for world leaders to maintain target commitments

On the first of the three-day U.N. Summit on the Millennium Development Goals (MDGs), U.N. Secretary-General Ban Ki-moon on Monday appealed "to the assembled presidents, prime ministers and kings to use their power to meet U.N. goals to help the world's poorest by 2015," the Associated Press reports.

22 Sep 2010

Clinton Global Initiative meeting kicks off, U.S. will commit to Clean Cookstove project

"World leaders, CEOs, non-governmental organizations and philanthropists" are gathering this week at the Clinton Global Initiative (CGI) annual meeting, "[t]imed to coincide with the beginning of the United Nations General Assembly," WNYC News reports (Herman, 9/20).

22 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.

21 Sep 2010

International activists ask: 'Will MDG summit fail HIV-positive people?'

A group of Russian AIDS activists are charging that the Russian Ministry of Health is denying that there are drug stock-outs that prevent patients from starting or continuing treatment. "In this situation, people with HIV face a choice: to die quietly at home or try to attract the attention of the government and the media," said Alexey Yaskovich, a Russian activist from Novgorod. "Therefore, activists will continue to go to the streets of Moscow and hold public events dedicated to saving their lives."

21 Sep 2010

Inovio Pharmaceuticals completes enrollment for PENNVAX-B vaccine Phase I clinical study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the Phase I clinical study assessing Inovio's PENNVAX-B DNA vaccine delivered using its proprietary electroporation technology in a preventive setting has fully completed the enrollment of 48 healthy volunteers. The multi-center study is being conducted by Inovio's clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites under a protocol designated HVTN-080.

21 Sep 2010

Global dementia costs hit $604 billion: World Alzheimer Report 2010

The total estimated worldwide costs of dementia are $604 billion in 2010, according to the newly released World Alzheimer Report 2010, The Global Economic Impact of Dementia from Alzheimer's Disease International (ADI), a London based, nonprofit, international federation of 73 national Alzheimer organizations, including the Alzheimer's Association (U.S.).

21 Sep 2010

U.N. MDG summit begins; UNAIDS data shows 22 African countries see drop in new HIV infections

"Ten years after world leaders set the most ambitious goals ever to tackle global poverty, they are meeting again to try to spur action to meet the targets by the 2015 deadline - which the U.N. says will be difficult, if not impossible, in some cases," the Associated Press reports. More than 140 world leaders are scheduled to participate in the three-day U.N. Summit on the Millennium Development Goals (MDGs), which kicks off Monday.

21 Sep 2010

Discovery could lead to new treatment methods for toxoplasmosis

The parasite responsible for toxoplasmosis requires a stress response system that helps it survive the move to infect new cells, Indiana University School of Medicine scientists have reported, a discovery that could lead to new treatments to control the disease.

21 Sep 2010

AIDS News and Research

Raltegravir could be valid target against all Herpesviridae

St. Jude Medical to highlight OCT product platform at TCT meeting

LSUHSC hosts international scientific conference on drug abuse research and politics

World leaders address country ownership, accountability, women at MDG summit

Merck expands patient assistance programs to provide medicines to needy people

Opinions: Genetically-modified crops can improve vaccines; MDG focus on women and girls; U.S. leadership for MDGs; Boosting access to drugs; Merits of bilateral development assistance

N.J. Democrats fail to restore funds to family-planning centers; Penn. reports record number eligible for Medicaid; N.Y. report suggests overhauling Medicaid system

UC researcher receives NIDA’s Avant-Garde Award for cocaine addiction research

NIDA's Avant-Garde Awards support novel approaches for treating tobacco and cocaine addiction

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Specific orofacial characteristics can lead to accurate diagnosis of fetal alcohol spectrum disorders

Secretary-General opens U.N. summit on MDGS with appeal for world leaders to maintain target commitments

Clinton Global Initiative meeting kicks off, U.S. will commit to Clean Cookstove project

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Annals of Internal Medicine publishes GRACE study data on HIV therapy

International activists ask: 'Will MDG summit fail HIV-positive people?'

Inovio Pharmaceuticals completes enrollment for PENNVAX-B vaccine Phase I clinical study

Global dementia costs hit $604 billion: World Alzheimer Report 2010

U.N. MDG summit begins; UNAIDS data shows 22 African countries see drop in new HIV infections

Discovery could lead to new treatment methods for toxoplasmosis

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News